Medical Advocates
Atazanavir (Reyataz)
 
Pediatric Data

New and Noteworthy
 Pharmacokinetics
 Adverse Events
 Efficacy
 Treatment Guidelines




 

  
Atazanavir Main Page New/Newsworthy Home Page      
Last updated:  June 01, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
March 2008
 
Drug Alerts
       
 
PACKAGE INSERT PDF UPDATE
 The Reyataz (atazanavir) Capsule label has been updated to include the
dosing recommendations for pediatric patients 6 to 18 years of age.
USFDA
March 26, 2008
 News Release
Pharmacokinetics
 

     Conference Reports, Abstracts, and Posters
 
  Pharmacokinetics of Atazanavir/Ritonavir in HIV-infected Infants, Children, and
Adolescents: PACTG 1020A
 J Kiser  R Rutstein , G Aldrovandi , et al
(12 CROI)
 Abstract
Adverse Events
 
     Conference Reports, Abstracts, and Posters
 
 
POSTER
 Changes in Cholesterol and Triglyceride Levels among Pediatric Patients Treated with
Atazanavir, with or without Ritonavir Boosting: The 1020A NIH PACTG Protocol
 P Samson, R Rutstein, T Fenton,  et al 
(13 CROI)
 PDF Poster     Abstract

Relationship between Low Bone Mass Measurements and Age in HIV-infected Children
and Adolescents on HAART
 S Mora, V Giacomet, L Cafarelli , et al
 (12 CROI)
 Abstract

Effect of Atazanavir on Serum Cholesterol and Triglyceride Levels in HIV-infected Infants,
Children, and Adolescents- PACTG 1020A
 R Rutstein, P Samson, G Aldrovandi, et al
 (12 CROI)
 Abstract
 
Trends in Bacteremia in the Pre- and Post-HAART Eras among HIV-infected Children
in the U.S. Perinatal AIDS Collaborative Transmission Study (1986-2004)
 S Nesheim, M oe, B Kapogiannis, et al
 Abstract
Efficacy
 

     Journal Abstracts, Papers, and Commentaries

  Change to a Once-Daily Combination Including Boosted Atazanavir in HIV-1-Infected Children.
 Macassa E, Delaugerre C, Teglas JP, et a 
Pediatr Infect Dis J. 2006 Sep;25(9):809-814.
 Abstract
 
     Conference Reports, Abstracts, and Posters
 
  POSTER
 Treatment Responses to Atazanavir-containing HAART in a Drug-naïve Pediatric Population
in South Africa
T Meyers R Rutstein, P Samson,
PDF Poster     Abstract
Treatment Guidelines
United States 
 

ARV Drugs Main Page New/Newsworthy Home Page      

Atazanavir Pediatric Data